Mechanism and Treatment of Rituximab Resistance in Diffuse Large Bcell Lymphoma

Curr Cancer Drug Targets. 2019;19(9):681-687. doi: 10.2174/1568009619666190126125251.

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype B non-Hodgkin lymphoma in adults. After rituximab being introduced to treat DLBCL, the current first-line treatment is R-CHOP regimen. This regimen greatly improves patient's prognosis, however, relapsed or refractory cases are commonly seen, mainly due to the resistance to rituximab. Although a large number of experiments have been conducted to investigate rituximab resistance, the exac mechanisms and solutions are still unclear. This review mainly explores the possible mechanisms oft rituximab resistance and current new effective treatments for rituximab resistance in DLBCL.

Keywords: CD20; Diffuse large B-cell lymphoma; biomarker; non-Hodgkin lymphoma; prognosis; rituximab resistance..

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Drug Resistance, Neoplasm*
  • Humans
  • Immunotherapy / methods*
  • Immunotherapy, Adoptive / methods*
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / pathology
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / pathology
  • Prednisone / administration & dosage
  • Prognosis
  • Rituximab / administration & dosage
  • Transcription Factor RelA / antagonists & inhibitors*
  • Transcription Factor RelA / metabolism
  • Vincristine / administration & dosage

Substances

  • RELA protein, human
  • Transcription Factor RelA
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone